PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Cited by (1,079)

Items 1,001–1,079 of 1,079

1. Fusobacterium and Colorectal Cancer
   Ziwei Zhou, Jiewen Chen, Herui Yao, Hai Hu · 2018 · Frontiers in Oncology
2. Current and future perspectives of PD-1/PDL-1 blockade in cancer immunotherapy
   Makuku, Rangarirai, Khalili, Neda, Razi, Sepideh, Keshavarz-Fathi, Mahsa, Rezaei, Nima · 2021 · Journal of Immunology Research
3. Immunotherapy comes of age: Immune aging & checkpoint inhibitors
   Elias, Rawad, Karantanos, Theodoros, Sira, Elizabeth, Hartshorn, Kevan L. · 2017 · Journal of Geriatric Oncology
4. Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials
   Costa, Ricardo, Carneiro, Benedito A., Agulnik, Mark, Rademaker, Alfred W., Pai, Sachin G., Villaflor, Victoria M., Cristofanilli, Massimo, Sosman, Jeffrey A., Giles, Francis J. · 2017 · Oncotarget
5. Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer
   Sforza, Vincenzo, Martinelli, Erika, Ciardiello, Fortunato, Gambardella, Valentina, Napolitano, Stefania, Martini, Giulia, della Corte, Carminia, Cardone, Claudia, Ferrara, Marianna L, Reginelli, Alfonso et al. · 2016 · World Journal of Gastroenterology
6. Colorectal cancer organoid-stroma biobank allows subtype-specific assessment of individualized therapy responses
   Farin, Henner F., Mosa, Mohammed H., Ndreshkjana, Benardina, Grebbin, Britta M., Ritter, Birgit, Menche, Constantin, Kennel, Kilian B., Ziegler, Paul K., Szabó, Lili, Bollrath, Julia et al. · 2023 · Cancer Discovery
7. Optimizing immunotherapy for colorectal cancer
   Ganesh, Karuna · 2022 · Nature Reviews Gastroenterology & Hepatology
8. Safety of nivolumab plus low-dose ipilimumab in previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer
   Morse, Michael A., Overman, Michael J., Hartman, Leighanne, Khoukaz, Taline, Brutcher, Edith, Lenz, Heinz-Josef, Atasoy, Ajlan, Shangguan, Tong, Zhao, Huanyu, El-Rayes, Bassel · 2019 · The Oncologist
9. Portrait of a cancer: mutational signature analyses for cancer diagnostics
   Van Hoeck, Arne, Tjoonk, Niels H., van Boxtel, Ruben, Cuppen, Edwin · 2019 · BMC Cancer
10. Why is pancreatic cancer so deadly? The pathologist's view
    Hruban, Ralph H, Gaida, Matthias M, Thompson, Elizabeth, Hong, Seung‐Mo, Noë, Michaël, Brosens, Lodewijk AA, Jongepier, Martine, Offerhaus, G Johan A, Wood, Laura D · 2019 · The Journal of Pathology
11. Morphological characterization of colorectal cancers in The Cancer Genome Atlas reveals distinct morphology–molecular associations: clinical and biological implications
    Shia, Jinru, Schultz, Nikolaus, Kuk, Deborah, Vakiani, Efsevia, Middha, Sumit, Segal, Neil H, Hechtman, Jaclyn F, Berger, Michael F, Stadler, Zsofia K, Weiser, Martin R et al. · 2017 · Modern Pathology
12. Epithelial and stromal co-evolution and complicity in pancreatic cancer
    Hingorani, Sunil R. · 2023 · Nature Reviews Cancer
13. Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA
    Chae, Young Kwang, Davis, Andrew A., Carneiro, Benedito A., Chandra, Sunandana, Mohindra, Nisha, Kalyan, Aparna, Kaplan, Jason, Matsangou, Maria, Pai, Sachin, Costa, Ricardo et al. · 2016 · Oncotarget
14. The role of biomarkers in personalized immunotherapy
    Sankar, Kamya, Ye, Jing Christine, Li, Zihai, Zheng, Lei, Song, Wenru, Hu-Lieskovan, Siwen · 2022 · Biomarker Research
15. Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma
    Goeppert, Benjamin, Roessler, Stephanie, Renner, Marcus, Singer, Stephan, Mehrabi, Arianeb, Vogel, Monika Nadja, Pathil, Anita, Czink, Elena, Köhler, Bruno, Springfeld, Christoph et al. · 2019 · British Journal of Cancer
16. The Cellular Immunotherapy Revolution: Arming the Immune System for Precision Therapy
    Paucek, Richard D., Baltimore, David, Li, Guideng · 2019 · Trends in Immunology
17. Rise of PD-L1 expression during metastasis of colorectal cancer: Implications for immunotherapy
    Wang, Huan Bin, Yao, Han, Li, Chu Shu, Liang, Lun Xi, Zhang, Yao, Chen, Ying Xuan, Fang, Jing‐Yuan, Xu, Jie · 2017 · Journal of Digestive Diseases
18. Multicenter phase I/II trial of napabucasin and pembrolizumab in patients with metastatic colorectal cancer (EPOC1503/SCOOP trial)
    Kawazoe, Akihito, Kuboki, Yasutoshi, Shinozaki, Eiji, Hara, Hiroki, Nishina, Tomohiro, Komatsu, Yoshito, Yuki, Satoshi, Wakabayashi, Masashi, Nomura, Shogo, Sato, Akihiro et al. · 2020 · Clinical Cancer Research
19. Whole-Genome Sequencing Reveals Breast Cancers with Mismatch Repair Deficiency
    Davies, Helen, Morganella, Sandro, Purdie, Colin A., Jang, Se Jin, Borgen, Elin, Russnes, Hege, Glodzik, Dominik, Zou, Xueqing, Viari, Alain, Richardson, Andrea L. et al. · 2017 · Cancer Research
20. Immune overdrive signature in colorectal tumor subset predicts poor clinical outcome
    Fakih, Marwan, Ouyang, Ching, Wang, Chongkai, Tu, Travis Yiwey, Gozo, Maricel C., Cho, May, Sy, Marvin, Longmate, Jeffrey A., Lee, Peter P. · 2019 · Journal of Clinical Investigation
21. Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses
    Lo, Jennifer A., Kawakubo, Masayoshi, Juneja, Vikram R., Su, Mack Y., Erlich, Tal H., LaFleur, Martin W., Kemeny, Lajos V., Rashid, Mamunur, Malehmir, Mohsen, Rabi, S. Alireza et al. · 2021 · Science Translational Medicine
22. U3-1402, a Novel HER3-Targeting Antibody-Drug Conjugate, for the Treatment of Colorectal Cancer
    Koganemaru, Shigehiro, Kuboki, Yasutoshi, Koga, Yoshikatsu, Kojima, Takashi, Yamauchi, Mayumi, Maeda, Naoyuki, Kagari, Takashi, Hirotani, Kenji, Yasunaga, Masahiro, Matsumura, Yasuhiro et al. · 2019 · Molecular Cancer Therapeutics
23. MSI/MMR-deficient tumor diagnosis: Which standard for screening and for diagnosis? Diagnostic modalities for the colon and other sites: Differences between tumors
    Svrcek, Magali, Lascols, Olivier, Cohen, Romain, Collura, Ada, Jonchère, Vincent, Fléjou, Jean-François, Buhard, Olivier, Duval, Alex · 2019 · Bulletin du Cancer
24. Endogenous CD4+ T Cells Recognize Neoantigens in Lung Cancer Patients, Including Recurrent Oncogenic <i>KRAS</i> and <i>ERBB2</i> ( <i>Her2</i> ) Driver Mutations
    Veatch, Joshua R., Jesernig, Brenda L., Kargl, Julia, Fitzgibbon, Matthew, Lee, Sylvia M., Baik, Christina, Martins, Renato, Houghton, A. McGarry, Riddell, Stanley R. · 2019 · Cancer Immunology Research
25. The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy
    Shi, Congqi, Qin, Kaiyu, Lin, Anqi, Jiang, Aimin, Cheng, Quan, Liu, Zaoqu, Zhang, Jian, Luo, Peng · 2022 · Journal of Experimental &amp; Clinical Cancer Research
26. The Evolutionary Landscape of Treatment for BRAFV600E Mutant Metastatic Colorectal Cancer
    Mauri, Gianluca, Bonazzina, Erica, Amatu, Alessio, Tosi, Federica, Bencardino, Katia, Gori, Viviana, Massihnia, Daniela, Cipani, Tiziana, Spina, Francesco, Ghezzi, Silvia et al. · 2021 · Cancers
27. The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1
    Derosa, Lisa, Routy, Bertrand, Kroemer, Guido, Zitvogel, Laurence · 2018 · OncoImmunology
28. Distinct PD-L1/PD1 profiles and clinical implications in intrahepatic cholangiocarcinoma patients with different risk factors
    Lu, Jia-Cheng, Zeng, Hai-Ying, Sun, Qi-Man, Meng, Qing-Nan, Huang, Xiao-Yong, Zhang, Peng-Fei, Yang, Xuan, Peng, Rui, Gao, Chao, Wei, Chuan-Yuan et al. · 2019 · Theranostics
29. Trial watch: immune checkpoint blockers for cancer therapy
    Vanpouille-Box, Claire, Lhuillier, Claire, Bezu, Lucillia, Aranda, Fernando, Yamazaki, Takahiro, Kepp, Oliver, Fucikova, Jitka, Spisek, Radek, Demaria, Sandra, Formenti, Silvia C. et al. · 2017 · OncoImmunology
30. Genome Sequencing during a Patient’s Journey through Cancer
    Nangalia, Jyoti, Campbell, Peter J. · 2019 · New England Journal of Medicine
31. Scientific rationale for combination immunotherapy of hepatocellular carcinoma with anti–PD-1/PD-L1 and anti–CTLA-4 antibodies
    Kudo, Masatoshi · 2019 · Liver Cancer
32. Measuring tumor mutation burden in non-small cell lung cancer: Tissue versus liquid biopsy
    Fenizia, Francesca, Pasquale, Raffaella, Roma, Cristin, Bergantino, Francesca, Iannaccone, Alessia, Normanno, Nicola · 2018 · Translational Lung Cancer Research
33. Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability–High/Mismatch Repair–Deficient Tumors
    Hollebecque, Antoine, Chung, Hyun C., de Miguel, Maria J., Italiano, Antoine, Machiels, Jean-Pascal, Lin, Chia-Chi, Dhani, Neesha C., Peeters, Marc, Moreno, Victor, Su, Wu-Chou et al. · 2021 · Clinical Cancer Research
34. Microsatellite Instability in Colorectal Cancers: Carcinogenesis, Neo-Antigens, Immuno-Resistance and Emerging Therapies
    Randrian, Violaine, Evrard, Camille, Tougeron, David · 2021 · Cancers
35. Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4
    van den Bulk, Jitske, Verdegaal, Els M. E., Ruano, Dina, Ijsselsteijn, Marieke E., Visser, Marten, van der Breggen, Ruud, Duhen, Thomas, van der Ploeg, Manon, de Vries, Natasja L., Oosting, Jan et al. · 2019 · Genome Medicine
36. Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) Patients beyond Microsatellite Instability
    Borelli, Beatrice, Antoniotti, Carlotta, Carullo, Martina, Germani, Marco Maria, Conca, Veronica, Masi, Gianluca · 2022 · Cancers
37. DNAH10 mutation correlates with cisplatin sensitivity and tumor mutation burden in small-cell lung cancer
    Li, Man, Lin, Anqi, Luo, Peng, Shen, Weitao, Xiao, Dan, Gou, Lanying, Zhang, Jian, Guo, Linlang · 2020 · Aging
38. ATM Mutations Benefit Bladder Cancer Patients Treated With Immune Checkpoint Inhibitors by Acting on the Tumor Immune Microenvironment
    Yi, Ruibin, Lin, Anqi, Cao, Manming, Xu, Abai, Luo, Peng, Zhang, Jian · 2020 · Frontiers in Genetics
39. Epigenetic Alteration in Colorectal Cancer: Potential Diagnostic and Prognostic Implications
    Cao, Qing, Tian, Ye, Deng, Zhiyi, Yang, Fangfang, Chen, Erfei · 2024 · International Journal of Molecular Sciences
40. Methylation-Based Therapies for Colorectal Cancer
    Cervena, Klara, Siskova, Anna, Buchler, Tomas, Vodicka, Pavel, Vymetalkova, Veronika · 2020 · Cells
41. Checkpoint immunotherapy in pediatrics: here, gone, and back again
    Long, Adrienne H., Morgenstern, Daniel A., Leruste, Amaury, Bourdeaut, Franck, Davis, Kara L. · 2022 · American Society of Clinical Oncology Educational Book
42. Genomic Assessment of Blood-Derived Circulating Tumor DNA in Patients With Colorectal Cancers: Correlation With Tissue Sequencing, Therapeutic Response, and Survival
    Kato, Shumei, Schwaederlé, Maria C., Fanta, Paul T., Okamura, Ryosuke, Leichman, Lawrence, Lippman, Scott M., Lanman, Richard B., Raymond, Victoria M., Talasaz, AmirAli, Kurzrock, Razelle · 2019 · JCO Precision Oncology
43. Biomarkers for Response to Immune Checkpoint Blockade
    Ganesan, Shridar, Mehnert, Janice · 2020 · Annual Review of Cancer Biology
44. Blockade of checkpoint receptor PVRIG unleashes anti-tumor immunity of NK cells in murine and human solid tumors
    Li, Yangyang, Zhang, Yu, Cao, Guoshuai, Zheng, Xiaodong, Sun, Cheng, Wei, Haiming, Tian, Zhigang, Xiao, Weihua, Sun, Rui, Sun, Haoyu · 2021 · Journal of Hematology &amp; Oncology
45. Patient-derived tumor models: a more suitable tool for pre-clinical studies in colorectal cancer
    Rizzo, Giulia, Bertotti, Andrea, Leto, Simonetta Maria, Vetrano, Stefania · 2021 · Journal of Experimental &amp; Clinical Cancer Research
46. Immune Checkpoint Inhibition in Metastatic Colorectal Cancer Harboring Microsatellite Instability or Mismatch Repair Deficiency
    Cohen, Romain, Colle, Raphaël, Pudlarz, Thomas, Heran, Maximilien, Duval, Alex, Svrcek, Magali, André, Thierry · 2021 · Cancers
47. Metastatic Colorectal Cancer in the Era of Personalized Medicine: A More Tailored Approach to Systemic Therapy
    Yu, Irene S., Cheung, Winson Y. · 2018 · Canadian Journal of Gastroenterology and Hepatology
48. Cholangiocarcinoma: Recent Advances in Molecular Pathobiology and Therapeutic Approaches
    Khosla, Divya, Misra, Shagun, Chu, Pek Lim, Guan, Peiyong, Nada, Ritambhra, Gupta, Rajesh, Kaewnarin, Khwanta, Ko, Tun Kiat, Heng, Hong Lee, Srinivasalu, Vijay Kumar et al. · 2024 · Cancers
49. Autophagy: A Versatile Player in the Progression of Colorectal Cancer and Drug Resistance
    Manzoor, Shaista, Muhammad, Jibran Sualeh, Maghazachi, Azzam A., Hamid, Qutayba · 2022 · Frontiers in Oncology
50. Mesothelioma Malignancy and the Microenvironment: Molecular Mechanisms
    Cersosimo, Francesca, Barbarino, Marcella, Lonardi, Silvia, Vermi, William, Giordano, Antonio, Bellan, Cristiana, Giurisato, Emanuele · 2021 · Cancers
51. Broad Detection of Alterations Predicted to Confer Lack of Benefit from EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer
    Rankin, Andrew, Klempner, Samuel J., Erlich, Rachel, Sun, James X., Grothey, Axel, Fakih, Marwan, George, Thomas J., Lee, Jeeyun, Ross, Jeffrey S., Stephens, Philip J. et al. · 2016 · The Oncologist
52. Targeting DNA Damage Response and Immune Checkpoint for Anticancer Therapy
    Huang, Jau-Ling, Chang, Yu-Tzu, Hong, Zhen-Yang, Lin, Chang-Shen · 2022 · International Journal of Molecular Sciences
53. Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression
    Napolitano, S., Matrone, N., Muddassir, A. L., Martini, G., Sorokin, A., De Falco, V., Giunta, E. F., Ciardiello, D., Martinelli, E., Belli, V. et al. · 2019 · Journal of Experimental &amp; Clinical Cancer Research
54. High Prevalence of Hereditary Cancer Syndromes and Outcomes in Adults with Early-Onset Pancreatic Cancer
    Bannon, Sarah A., Montiel, Maria F., Goldstein, Jennifer B., Dong, Wenli, Mork, Maureen E., Borras, Ester, Hasanov, Merve, Varadhachary, Gauri R., Maitra, Anirban, Katz, Matthew H. et al. · 2018 · Cancer Prevention Research
55. Tumor Infiltrating Regulatory T Cells in Sporadic and Colitis-Associated Colorectal Cancer: The Red Little Riding Hood and the Wolf
    Fantini, Massimo Claudio, Favale, Agnese, Onali, Sara, Facciotti, Federica · 2020 · International Journal of Molecular Sciences
56. Upregulation of PD-1 follows tumour development in the AOM/DSS model of inflammation-induced colorectal cancer in mice
    Yassin, Mohammad, Sadowska, Zuzanna, Djurhuus, Ditte, Nielsen, Brian, Tougaard, Peter, Olsen, Jørgen, Pedersen, Anders Elm · 2019 · Immunology
57. Network approach in liquidomics landscape
    Santini, Daniele, Botticelli, Andrea, Galvano, Antonio, Iuliani, Michele, Incorvaia, Lorena, Gristina, Valerio, Taffon, Chiara, Foderaro, Simone, Paccagnella, Elisa, Simonetti, Sonia et al. · 2023 · Journal of Experimental &amp; Clinical Cancer Research
58. Current and emerging concepts for systemic treatment of metastatic colorectal cancer
    Steup, Christoph, Kennel, Kilian B, Neurath, Markus F, Fichtner-Feigl, Stefan, Greten, Florian R · 2025 · Gut
59. Colorectal Cancer Immunotherapy: State of the Art and Future Directions
    Cornista, Alyssa Mauri, Giolito, Maria Virginia, Baker, Kristi, Hazime, Hajar, Dufait, Inès, Datta, Jashodeep, Khumukcham, Saratchandra Singh, De Ridder, Mark, Roper, Jatin, Abreu, Maria T. et al. · 2023 · Gastro Hep Advances
60. Bintrafusp Alfa, an Anti-PD-L1:TGFβ Trap Fusion Protein, in Patients with ctDNA-positive, Liver-limited Metastatic Colorectal Cancer
    Morris, Van K., Overman, Michael J., Lam, Michael, Parseghian, Christine M., Johnson, Benny, Dasari, Arvind, Raghav, Kanwal, Kee, Bryan K., Huey, Ryan, Wolff, Robert A. et al. · 2022 · Cancer Research Communications
61. Genetic and pharmacological modulation of DNA mismatch repair heterogeneous tumors promotes immune surveillance
    Amodio, Vito, Lamba, Simona, Chilà, Rosaria, Cattaneo, Chiara M., Mussolin, Benedetta, Corti, Giorgio, Rospo, Giuseppe, Berrino, Enrico, Tripodo, Claudio, Pisati, Federica et al. · 2023 · Cancer Cell
62. The Therapeutic Landscape for KRAS-Mutated Colorectal Cancers
    Tria, Simon Manuel, Burge, Matthew E., Whitehall, Vicki L. J. · 2023 · Cancers
63. Karyotypic Aberrations in Oncogenesis and Cancer Therapy
    Vitale, Ilio, Manic, Gwenola, Senovilla, Laura, Kroemer, Guido, Galluzzi, Lorenzo · 2015 · Trends in Cancer
64. DNA Polymerase ε Deficiency Leading to an Ultramutator Phenotype: A Novel Clinically Relevant Entity
    Castellucci, Enrico, He, Tianfang, Goldstein, D. Yitzchak, Halmos, Balazs, Chuy, Jennifer · 2017 · The Oncologist
65. Colitis after checkpoint blockade: a retrospective cohort study of melanoma patients requiring admission for symptom control
    Hughes, Michael S., Zheng, Hui, Zubiri, Leyre, Molina, Gabriel E., Chen, Steven T., Mooradian, Meghan J., Allen, Ian M., Reynolds, Kerry L., Dougan, Michael · 2019 · Cancer Medicine
66. Learning from the Proteasome How To Fine-Tune Cancer Immunotherapy
    Vigneron, Nathalie, Abi Habib, Joanna, Van den Eynde, Benoit J. · 2017 · Trends in Cancer
67. Systemic Therapy for Metastatic Colorectal Cancer: From Current Standards to Future Molecular Targeted Approaches
    Atreya, Chloe E., Yaeger, Rona, Chu, Edward · 2017 · American Society of Clinical Oncology Educational Book
68. Immunotherapy in Glioblastoma: A Clinical Perspective
    Desbaillets, Nicolas, Hottinger, Andreas Felix · 2021 · Cancers
69. Pembrolizumab for advanced cervical cancer: Safety and efficacy
    De Felice, Francesca, Giudice, Elena, Bolomini, Giulia, Distefano, Maria Grazia, Scambia, Giovanni, Fagotti, Anna, Marchetti, Claudia · 2021 · Expert Review of Anticancer Therapy
70. Targeting autophagy as a therapeutic strategy against pancreatic cancer
    Yamamoto, Keisuke, Iwadate, Dosuke, Kato, Hiroyuki, Nakai, Yousuke, Tateishi, Keisuke, Fujishiro, Mitsuhiro · 2022 · Journal of Gastroenterology
71. Neratinib-Plus-Cetuximab in Quadruple-WT ( <i>KRAS, NRAS, BRAF, PIK3CA</i> ) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study
    Jacobs, Samuel A., Lee, James J., George, Thomas J., Wade, James L., Stella, Philip J., Wang, Ding, Sama, Ashwin R., Piette, Fanny, Pogue-Geile, Katherine L., Kim, Rim S. et al. · 2021 · Clinical Cancer Research
72. Functional and spatial proteomics profiling reveals intra- and intercellular signaling crosstalk in colorectal cancer
    Plattner, Christina, Lamberti, Giorgia, Blattmann, Peter, Kirchmair, Alexander, Rieder, Dietmar, Loncova, Zuzana, Sturm, Gregor, Scheidl, Stefan, Ijsselsteijn, Marieke, Fotakis, Georgios et al. · 2023 · iScience
73. Interconnectivity between molecular subtypes and tumor stage in colorectal cancer
    Coebergh van den Braak, R. R. J., ten Hoorn, S., Sieuwerts, A. M., Tuynman, J. B., Smid, M., Wilting, S. M., Martens, J. W. M., Punt, C. J. A., Foekens, J. A., Medema, J. P. et al. · 2020 · BMC Cancer
74. Ileal immune tonus is a prognosis marker of proximal colon cancer in mice and patients
    Picard, Marion, Yonekura, Satoru, Slowicka, Karolina, Petta, Ioanna, Rauber, Conrad, Routy, Bertrand, Richard, Corentin, Iebba, Valerio, Tidjani Alou, Maryam, Becharef, Sonia et al. · 2021 · Cell Death &amp; Differentiation
75. Clinical course and outcome of patients with high-level microsatellite instability cancers in a real-life setting: a retrospective analysis
    Halpern, Naama, Goldberg, Yael, Kadouri, Luna, Duvdevani, Morasha, Hamburger, Tamar, Peretz, Tamar, Hubert, Ayala · 2017 · OncoTargets and Therapy
76. Recent Advances in Our Knowledge of mCRC Tumor Biology and Genetics: A Focus on Targeted Therapy Development
    Gmeiner, William H · 2021 · OncoTargets and Therapy
77. Case Report: Dual Checkpoint Inhibition in Advanced Metastatic Osteosarcoma Results in Remission of All Tumor Manifestations—A Report of a Stunning Success in a 37-Year-Old Patient
    Sterz, Ulrich, Grube, Matthias, Herr, Wolfgang, Menhart, Karin, Wendl, Christina, Vogelhuber, Martin · 2021 · Frontiers in Oncology
78. Harnessing Microbiota to Improve Immunotherapy for Gastrointestinal Cancers
    Goc, Jeremy, Sonnenberg, Gregory F. · 2022 · Cancer Immunology Research
79. PathTIGR: A pathway topology-informed graph representation learning framework for immunotherapy response prediction
    Li X, He Y, Wu J, Wang Z, Zhao X, Zhang Y, Pan B, Tang Y, Han J · 2026 · PubMed